Single-use devices not suitable for reprocessing, says EU scientific panel
This article was originally published in Clinica
Reprocessing of single-use medical devices (SUDs) may pose several potential hazards and put patients at risk, the European Commission’s independent Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) has concluded.
You may also be interested in...
Drug companies in the EU explain how a new pilot scheme on national-level scientific advice service can benefit drug developers.
While the Dutch government negotiates an acceptable price for Leadiant Biosciences’ orphan drug CDCA, a university hospital has resumed supplying pharmacy compounded versions of the drug after addressing initial problems with the sourcing of raw materials.
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.